next guest taking a closer look at the charts here. Joining me now BTI market technician Jonathan Krinsky. It's good to have you back and a perfect reason to.What do you think here. >> Hey Scott. Yeah, so we were on a couple weeks ago talking about just when they launched the meme ETF which had gone dormant since November of 2023 and how the prior launch of it back in uh November of 2021 kind of marked the peak of that. And you know, so far, if we look at the meme index, uh it's pretty much coincided, the p ...

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=173228&from=3 CLASS PERIOD: May 7, 2025 to August ...

I'm not going anywhere, right. I I got all the money I need. The idea of me I mean screwing up the healthcare industry, that's better than putting your name on a building.is better than anything else because there's nobody in the history of everybody in this country who likes the way the cost of healthcare is and the cost of medication. ...

Accessible version BofA Securities Equity Client Flow Trends Institutional & retail clients bought the dip Biggest single stock inflows in over a year Inflows across sectors, led by Communication Services ETF outflows (but small cap ETF & style ETF inflows) Exhibit 3: Record buy-the-dip week for stocks: single stock inflows were the 5th-largest in history and the biggest ever for a week the market was down at least 1% Weekly net buying of single stocks by BofA Securities clients ($mn; 2008-10/10/25) Source: ...

Joining us now, a Democratic Congressman from Maryland, Glenn Ivy, who represents about 65,000 federal workers. Congresswoman, welcome. Um, you just heard AOC there.Do you agree with her that Democrats are looking for a long-term solution. They don't want any kind of a quick band-aid fix. Well, I think her uh political analysis is right there for sure.And couple points in addition, keep in mind that when it came to extending the tax cuts for the wealthiest Americans, the House Republicans and the Senate Rep ...

Amazon’s One Medical is expanding into pediatric care with a new pay-per-visit virtual health service for children ages 2 to 11. Starting at $29 for message-based visits and $49 for video calls, the service treats common conditions like pink eye, eczema... https://t.co/fLL4H55Fta ...

Core Insights - The Healthtech sector is experiencing a significant shift towards AI-enabled provider operations, which accounted for 44% of overall Healthtech investment in 2025, marking the highest investment levels since 2022 [1][2] - A total of $5.5 billion has been invested in healthcare provider operations, with projections indicating a full-year investment of $8.25 billion, surpassing the previous record of $7.8 billion set in 2021 [1][6] - The focus of investment is shifting from clinical care to operational tools, as AI is utilized to enhance efficiency in healthcare delivery [1][4] Investment Trends - Provider operations have seen a dramatic increase in investment, rising from 19% of Healthtech investment four years ago to nearly 50% in 2025 [1][6] - Alternative care investment has decreased significantly, accounting for only 9% of Healthtech investment in 2025, down from 42% in 2021 [1][6] - The total expected investment in Healthtech by the end of 2025 is projected to reach $18.5 billion [6] M&A Activity - There have been 32 mergers and acquisitions (M&A) deals in provider operations in 2025, with consolidation becoming a key exit strategy for investors [6] - 52% of the deals in 2025 have involved AI technologies, indicating a strong trend towards integrating AI in Healthtech [6] Valuation Insights - Generalist investors have added a valuation premium of 22% to mega-deals, which represent 38% of total Healthtech investment this year [6] - Seed-stage AI valuations have increased by approximately 42% since 2021, reflecting growing confidence in AI solutions [6] Trust in AI - Physicians express a high level of trust in AI for work efficiency (75%), but show significant concern regarding patient privacy, with only 15% trusting AI in this aspect [6]

Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated a grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 due to preliminary third-quarter revenue results falling below estimates and a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% increase the previous day following Novo Nordisk's acquisition of its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain the previous day [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 following CEO Subodh K. Kulkarni's sale of 1,000,000 shares, raising concerns about leadership commitment [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]

Group Financial Performance and Strategy - Merck aims to drive sustainable value creation as a leading science & technology company[7] - The company is actively managing its portfolio, focusing on attractive markets and solid competitive positions, with >80% of businesses in each category[10, 11] - Merck confirms M&A guardrails and financial discipline, with ongoing scouting for further M&A to accelerate growth[18] - The company is committed to topline growth and margin expansion mid-term[72] - Merck is on track to meet its 2025 guidance and has a positive early indication for 2026, with an expected EBITDA pre margin of ~29% in 2025[69, 70] Key Growth Drivers - Key growth drivers explain up to 80% of future growth, focusing on secular growth markets[20] - Process Solutions market segment continues to grow at a 9% to 10% CAGR[37] - Semiconductor Solutions contribute over 80% to Electronics sales mid-term[50] - Healthcare mid-term growth ambition is raised, driven by Rare Diseases uptake, targeting LSD to MSD organic sales growth (CAGR in %)[46] Life Science Strategy - Life Science is centering the business on three distinct go-to-market approaches: Process Solutions (~€35 billion), Advanced Solutions (~€47 billion), and Discovery Solutions (~€29 billion)[32]

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Summary by Relevant Sections Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's price point and revenue growth [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative of the class or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].